

	Overall survival		Event-free survival	
A.	HR (95% CI)	<i>P</i> *	HR (95% CI)	<i>P</i> *
<i>CEBPA</i> <sup>single-mut †</sup>	1.08 (0.48 – 2.45)	0.85	1.55 (0.72 – 3.33)	0.26
<i>CEBPA</i> <sup>double-mut †</sup>	0.31 (0.15 – 0.61)	<0.001*	0.34 (0.19 – 0.62)	<0.001*
Intermediate‡	2.50 (1.67 – 3.74)	<0.001*	2.24 (1.57 – 3.21)	<0.001*
Poor‡	3.74 (2.48 – 5.65)	<0.001*	3.06 (2.11 – 4.43)	<0.001*
Age [decades]	1.13 (1.02 – 1.26)	0.019*	1.09 (0.99 – 1.20)	0.093
WBC <sup>§</sup>	1.35 (1.04 – 1.75)	0.024*	1.31 (1.03 – 1.67)	0.029*
<i>FLT3</i> -ITD <sup> </sup>	1.59 (1.19 – 2.11)	0.0014*	1.44 (1.10 – 1.89)	0.0088*
<i>NPM1</i> <sup> </sup>	0.50 (0.37 – 0.69)	<0.001*	0.47 (0.35 – 0.63)	<0.001*
B.	HR (95% CI)	<i>P</i> *	HR (95% CI)	<i>P</i> *
<i>CEBPA</i> <sup>single-mut †</sup>	1.81 (0.72 – 4.56)	0.21	1.46 (0.57 – 3.61)	0.44
<i>CEBPA</i> <sup>double-mut †</sup>	0.43 (0.22 – 0.86)	0.017*	0.45 (0.24 – 0.84)	0.012*
Age [decades]	1.16 (1.01 – 1.32)	0.035*	1.06 (0.94 – 1.20)	0.33
WBC <sup>§</sup>	1.83 (1.22 – 2.74)	0.0035*	1.40 (0.96 – 2.04)	0.079
<i>FLT3</i> -ITD <sup> </sup>	1.59 (1.09 – 2.32)	0.016*	1.57 (1.10 – 2.25)	0.012*
<i>NPM1</i> <sup> </sup>	0.47 (0.32 – 0.70)	<0.001*	0.48 (0.33 – 0.70)	<0.001*

HR indicates hazard ratio; CI, confidence interval; WBC, white blood cell count, *FLT3*, fms-related tyrosine kinase 3; ITD, internal tandem duplication; and *NPM1*, nucleophosmin.

\* *P* value < 0.05

† *CEBPA* status versus *CEBPA*<sup>wt</sup>

‡ Cytogenetic risk versus cytogenetic good risk § White blood cell count higher than  $20 \times 10^9/L$  versus lower than  $20 \times 10^9/L$

| *FLT3*-ITD versus no *FLT3*-ITD

| *NPM1* mutation versus no *NPM1* mutation